Cost Of Revenue - Cutia Therapeutics (HKEX:2487) - Alpha Spread
C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 14.06 HKD -0.28% Market Closed
Market Cap: 4.3B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Cutia Therapeutics
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cutia Therapeutics
Cost of Revenue Peer Comparison

Comparables:
6160
1801
9926
603392
300122

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Cost of Revenue
-ÂĄ66.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cost of Revenue
-ÂĄ2.7B
CAGR 3-Years
-77%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cost of Revenue
-ÂĄ1.1B
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Cost of Revenue
-ÂĄ137.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cost of Revenue
-ÂĄ992.7m
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cost of Revenue
-ÂĄ35.1B
CAGR 3-Years
-49%
CAGR 5-Years
-51%
CAGR 10-Years
-62%

See Also

What is Cutia Therapeutics's Cost of Revenue?
Cost of Revenue
-66.6m CNY

Based on the financial report for Dec 31, 2023, Cutia Therapeutics's Cost of Revenue amounts to -66.6m CNY.

What is Cutia Therapeutics's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-1 842%

Over the last year, the Cost of Revenue growth was -1 842%.

Back to Top